Camp4 Therapeutics Corp
CAMP · Pharmaceutical Preparations · 51.9M shares · +1087%/yr ↑ dilution · EDGAR filings ↗
Reference price $1.53 · est. market cap ~$79M — last insider purchase, 2025-09-11 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — RNA-based clinical, well-funded.
Strengths
- Liquidity — current ratio 7.4 (71st)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Cash burnNegative free cash flow (-29.8M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +1087%/yr over 1y (dilution, book value/share -94%)
- Net lossNet loss (net margin -2298.5%)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Strong balance sheetStrong balance sheet — $110M cash & investments, ~15 quarters of runway
- Notable holderHeld by 3 notable fund(s): FMR LLC, STATE STREET CORP, GOLDMAN SACHS GROUP INC (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-1502.4%
Net margin
-2298.5%
Return on equity
-168.5%
Return on assets
-68.2%
Revenue growth (QoQ)
271.8%
Current ratio
7.4×
Free cash flow
-$30M
EBITDA
-$51M
Tangible book value
$48M
Cash & investments
$110M
Cash runway
15q
Stock comp / revenue
114.3%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-09-11 | Schwab Andrew J. | Grant | 2.9M | $1.53 |
| 2025-09-11 | 5AM Partners VI, LLC | Buy | 2.9M | $1.53 |
| 2025-09-11 | Gold Kelly | Buy | 6.1K | $1.65 |
| 2025-09-11 | Mandel-Brehm Josh | Buy | 6.1K | $1.65 |
| 2025-09-11 | Maricich Yuri | Buy | 6.1K | $1.65 |
| 2025-09-11 | Young Richard A | Buy | 15K | $1.65 |
| 2025-09-11 | Polaris Management Co. VII, L.L.C. | Buy | 1.2M | $1.53 |
| 2025-09-11 | Polaris Management Co. VII, L.L.C. | Buy | 85K | $1.53 |
| 2025-09-11 | Nashat Amir | Buy | 1.2M | $1.53 |
| 2025-09-11 | Nashat Amir | Buy | 85K | $1.53 |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-12 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-05-14 | Reg FDExhibits | filing ↗ |
| 2026-05-07 | ResultsExhibits | filing ↗ |
| 2026-03-24 | Exec/director change | filing ↗ |
| 2026-03-05 | Acquisition/dispositionReg FDExhibits | filing ↗ |
| 2026-01-09 | Reg FDExhibits | filing ↗ |
| 2025-12-23 | Material agreement1.02 | filing ↗ |
| 2025-12-18 | Material agreementReg FDExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-12 | 2026-06-10 | 0001628280-26-042846 ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | 0001736730-26-000033 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001628280-26-032146 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001628280-26-032096 ↗ |
| 8-K | 2026-03-24 | 2026-03-18 | 0001736730-26-000021 ↗ |
| 10-K | 2026-03-05 | 2025-12-31 | 0001736730-26-000016 ↗ |
| 8-K | 2026-03-05 | 2026-03-05 | 0001736730-26-000015 ↗ |
| 8-K | 2026-01-09 | 2026-01-09 | 0001736730-26-000004 ↗ |
| 8-K | 2025-12-23 | 2025-12-22 | 0001736730-25-000116 ↗ |
| 8-K | 2025-12-18 | 2025-12-17 | 0001736730-25-000111 ↗ |
| 8-K | 2025-12-18 | 2025-12-18 | 0001628280-25-058009 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001736730-25-000092 ↗ |